The U.S. Food and Drug Administration today approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perio
Similar Posts
Summary Metrics of Drug Development Tool Qualification Projects Submitted to FDA
This Table provides the current number of active CDER Drug Development Tool (DDT) Qualification projects overall and by Program (DDT- Animal Model Qualification Program, DDT- Biomarker Qualification Program, DDT- Clinical Outcomes Assessment [COA] Qualification Program). Numbers are also provided byNonprescription Drugs Advisory Committee Roster
This page contains the Nonprescription Drugs Advisory Committee Roster, which lists the current members and the current number of vacancies for the committee.Rhino 11 Gummy may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Rhino 11 Gummy, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Estaderma – 718714 – 11/03/2025
Unapproved New Drugs/Misbranded BotoxEarly Alert: Broselow Rainbow Tape Issue from AirLife
AirLife is removing Broselow Rainbow Tapes due to incorrectly printed medication dosing information.Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
LANSING, Mich. – (BUSINESS WIRE) – Neogen Corporation (NASDAQ: NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a th